VFY — Vitrafy Life Sciences Share Price
Last trade - 00:00- AU$92.58m
- AU$115.92m
- AU$0.04m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2,490.77 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -23199.87% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | n/a | n/a | n/a | 0.03 | 0.04 | 1.05 | 8.19 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vitrafy Life Sciences Limited is an Australia-based company focused on the advancement of biomedical cryopreservation. It is engaged in research, development and commercialization of its vertically integrated cryopreservation solution that includes cryopreservation medical devices (freezer, thawer and packaging solutions), LifeChain integrated software system, and application services for identified application areas in human health and animal health services. Its patented algorithm calculates the required operating conditions for biomaterial cryopreservation and informs the cryopreservation technologies' automation software of precise operating conditions to deliver optimum cell survivability. Its Lifechain software platform combines the advanced software functions, such as artificial intelligence (AI), machine learning and IoMT integration, to ensure supply chain processes are controlled, traced, tracked and monitored to the standards, and retain the quality of precious biomaterials.
Directors
- Last Annual
- June 30th, 2024
- Last Interim
- January 1st, 1970
- Incorporated
- November 8th, 2017
- Public Since
- November 26th, 2024
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 63,849,674
- Address
- Level 4, 96 100 Albert Road, SOUTH MELBOURNE, 3205
- Web
- https://vitrafy.com/
- Phone
- Auditors
- Grant Thornton Audit Pty Ltd
Similar to VFY
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
Aroa Biosurgery
Australian Stock Exchange - SEATS
FAQ
As of Today at 24:01 UTC, shares in Vitrafy Life Sciences are trading at AU$1.45. This share price information is delayed by 15 minutes.
Shares in Vitrafy Life Sciences last closed at AU$1.45 and the price had moved by over the past 365 days. In terms of relative price strength the Vitrafy Life Sciences share price has matched the ASX All Ordinaries Index by over the past year.
The overall consensus recommendation for Vitrafy Life Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreVitrafy Life Sciences does not currently pay a dividend.
Vitrafy Life Sciences does not currently pay a dividend.
Vitrafy Life Sciences does not currently pay a dividend.
To buy shares in Vitrafy Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$1.45, shares in Vitrafy Life Sciences had a market capitalisation of AU$92.58m.
Here are the trading details for Vitrafy Life Sciences:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: VFY
Based on an overall assessment of its quality, value and momentum Vitrafy Life Sciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Vitrafy Life Sciences is AU$2.15. That is 47.93% above the last closing price of AU$1.45.
Analysts covering Vitrafy Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of -AU$23.43 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vitrafy Life Sciences. Over the past six months, its share price has matched the ASX All Ordinaries Index by .
As of the last closing price of AU$1.45, shares in Vitrafy Life Sciences were trading -6.49% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Vitrafy Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$1.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Vitrafy Life Sciences' directors